Nvidia Corp. expanded its presence in life sciences AI through separate initiatives with Certara Inc. and Silo Pharma Inc. Certara is integrating Nvidia’s BioNeMo Agent Toolkit into its AI-driven drug development platform, while Silo Pharma’s subsidiary, QwikAgents, has joined the Nvidia Developer Program to strengthen its AI agent capabilities.

Certara Integrates Nvidia BioNeMo Into AI Drug Development Platform

Certara is partnering with Nvidia to advance its open, integrated AI platform by combining its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. Under the collaboration, the Nvidia BioNeMo Agent Toolkit will become one of several agentic frameworks available within Certara’s platform. The toolkit is designed to turn AI agents into autonomous life sciences researchers by providing access to Nvidia’s life sciences technology stack while complementing Certara’s biosimulation models, regulatory expertise, and scientific teams.

AI Agents Target Drug Development Workflows

Specialized AI agents will analyze scientific models, datasets, and domain expertise across multiple stages of drug development. These agents can support tasks such as optimizing dosing strategies using systems pharmacology models, analyzing clinical datasets, simulating patient and clinical trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence, and assessing early-stage drug discovery hypotheses. The technology is intended to enhance the work of biosimulation experts and scientific teams by accelerating insight generation while keeping scientists at the center of decision-making.

Silo Pharma Subsidiary Joins Nvidia Developer Program

Silo Pharma announced its wholly owned subsidiary, QwikAgents, has joined the Nvidia Developer Program. QwikAgents’ platform automates complex workflows using autonomous AI agents capable of reasoning, taking action, and interacting with enterprise systems. The platform also incorporates persistent memory, intelligent routing across multiple large language model providers, browser automation, and secure data management to support scalable AI-driven operations. Participation in the Nvidia Developer Program will provide QwikAgents with access to Nvidia’s AI software ecosystem, development frameworks, technical training, and optimization resources. Silo Pharma expects these resources to help accelerate platform enhancements as it expands AI agent capabilities for enterprise customers.

Nvidia Corporation shares are trading lower following reports suggesting China’s DeepSeek is developing AI chips for inference, which reduces its reliance on the company. The potential shift in strategy by a major AI player poses a risk to Nvidia's dominance in the semiconductor market, as inference chips are critical for running trained models. Nvidia stock was down 1.62% at $192.39 at the time of publication.

DeepSeek’s Quiet Push Into Semiconductors

According to Reuters, DeepSeek is developing its own AI chip designed for inference — the stage of AI computing in which a trained model generates responses for users — rather than for training new models. The effort began approximately a year ago and remains at an early stage, with DeepSeek reaching out to external chip-design, foundry and memory companies. The company has also quietly increased hiring of chip-design engineers in recent months without posting public job listings.

If successful, the move would mark a major strategic shift for DeepSeek — widely regarded as China’s AI champion — and could reduce its reliance on both Nvidia and Huawei chips, which it has historically depended on to train and run its globally popular models.

The Broader Context

DeepSeek would be joining a growing list of AI companies seeking to reduce dependence on Nvidia by developing custom silicon. OpenAI last month unveiled Jalapeño, its first custom inference chip developed with Broadcom, while Anthropic has been weighing building its own chips, Reuters reported in April.